ID
25664
Beskrivning
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Status of treatment blind.
Nyckelord
Versioner (2)
- 2017-08-18 2017-08-18 -
- 2017-09-08 2017-09-08 -
Uppladdad den
8 september 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Status of treatment blind GSK study Dyskinesia in Parkinson's disease NCT00363727
Status of treatment blind GSK study Dyskinesia in Parkinson's disease NCT00363727
Similar models
Status of treatment blind GSK study Dyskinesia in Parkinson's disease NCT00363727
C0678257 (UMLS CUI [1,2])
C2347038 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
C0205394 (UMLS CUI [1,2])
C1518544 (UMLS CUI [1,3])
C0678257 (UMLS CUI [1,4])